Literature DB >> 32143002

Sirtuin 6 attenuates epithelial-mesenchymal transition by suppressing the TGF-β1/Smad3 pathway and c-Jun in asthma models.

Fen Liu1, Yun-Xiao Shang2.   

Abstract

Allergic asthma is a chronic inflammatory airway disease involving airway remodeling. The histone deacetylase sirtuin6 (SIRT6) has protective effects in cardiac and liver fibrosis; however, its role in airway remodeling is unclear. In this study, we investigated the expression of SIRT6 in a rat model of airway remodeling and observed its effects on the epithelial-mesenchymal transition (EMT) in human bronchial epithelial 16HBE cells. Sprague-Dawley rats were sensitized and challenged with ovalbumin to induce airway remodeling or with phosphate-buffered saline as a control for different periods. Morphological changes, cell counts in the bronchoalveolar lavage fluid, and SIRT6 expression were assessed. 16HBE cells were transfected with plasmids to silence or overexpress SIRT6. Western blotting, quantitative polymerase chain reaction, Transwell assays, and cell proliferation assays were performed to examine the transforming growth factor (TGF)-β1-induced changes in EMT indicators and EMT-related cell behaviors. SIRT6 expression was upregulated in bronchial epithelial cells from rats with airway remodeling and in TGF-β1-treated 16HBE cells. SIRT6 overexpression affected TGF-β1-induced changes in EMT markers and EMT-like cell behaviors. In particular, SIRT6 overexpression alleviated the reduction in E-cadherin and the increases in N-cadherin, vimentin, alpha-smooth muscle actin, and metalloproteinase-9 levels in TGF-β1-treated 16HBE cells. Forced expression of SIRT6 also decreased the rates of cell migration and proliferation, reduced activation of phosphorylated Smad3 induced by TGF-β1 treatment, suppressed the acetylation level at histone H3K9, and inhibited the transcriptional activity of the c-Jun promotor. These results suggested that SIRT6 expression is upregulated during airway remodeling and modulates EMT in bronchial epithelial cells targeting Smad3 and c-Jun, highlighting a new therapeutic candidate for improving airway remodeling in asthma.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Airway remodeling; Asthma; Epithelial–mesenchymal transition; Sirtuin 6

Year:  2020        PMID: 32143002     DOI: 10.1016/j.intimp.2020.106333

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  Sigma-1 Receptor Alleviates Airway Inflammation and Airway Remodeling Through AMPK/CXCR4 Signal Pathway.

Authors:  Te Jiang; Di Zhao; Zhiyuan Zheng; Zhankui Li
Journal:  Inflammation       Date:  2022-01-14       Impact factor: 4.092

2.  Sinomenine Relieves Airway Remodeling By Inhibiting Epithelial-Mesenchymal Transition Through Downregulating TGF-β1 and Smad3 Expression In Vitro and In Vivo.

Authors:  Hongjuan He; Lihua Cao; Zheng Wang; Zhenzhen Wang; Jinxin Miao; Xiu-Min Li; Mingsan Miao
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

Review 3.  Role of Histone Post-Translational Modifications in Inflammatory Diseases.

Authors:  Yingying Lin; Ting Qiu; Guifeng Wei; Yueyue Que; Wenxin Wang; Yichao Kong; Tian Xie; Xiabin Chen
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

4.  The TL1A-DR3 Axis in Asthma: Membrane-Bound and Secreted TL1A Co-Determined the Development of Airway Remodeling.

Authors:  Jintao Zhang; Dong Zhang; Yun Pan; Xiaofei Liu; Jiawei Xu; Xinrui Qiao; Wenjing Cui; Liang Dong
Journal:  Allergy Asthma Immunol Res       Date:  2022-03       Impact factor: 5.764

Review 5.  Roles of sirtuins in asthma.

Authors:  Yahui Liu; Guochao Shi
Journal:  Respir Res       Date:  2022-09-18

6.  FOXO3a Protects against Kidney Injury in Type II Diabetic Nephropathy by Promoting Sirt6 Expression and Inhibiting Smad3 Acetylation.

Authors:  Xiaowei Wang; Tingting Ji; Xiaoying Li; Xiaolei Qu; Shoujun Bai
Journal:  Oxid Med Cell Longev       Date:  2021-05-26       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.